Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.39 |
| ▸ | FABP7 | O15540 | 2/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1913192 | 1.00 | KMT2A (0.43) | KMT2AL3MBTL1BTKKDM1AMAOB | |
| SCHEMBL1913190 | 1.00 | KMT2A (0.43) | KMT2AL3MBTL1BTKKDM1AMAOB | |
| SCHEMBL1913212 | 1.00 | KMT2A (0.43) | KMT2AL3MBTL1BTKKDM1AMAOB | |
| SCHEMBL14428332 | 0.93 | KMT2A (0.44) | KMT2AL3MBTL1KDM1AMAOBTLR2 | |
| SCHEMBL8249851 | 0.91 | KMT2A (0.40) | KMT2AL3MBTL1KDM1AMAOBTLR2 | |
| SCHEMBL19180879 | 0.91 | KMT2A (0.40) | KMT2AL3MBTL1KDM1AMAOBTLR2 | |
| SCHEMBL17101875 | 0.88 | KMT2A (0.41) | KMT2AL3MBTL1KDM1AMAOBTLR2 | |
| SCHEMBL4503172 | 0.87 | TLR2 (0.41) | KMT2AL3MBTL1KDM1AMAOBTLR2 | |
| SCHEMBL4503171 | 0.87 | TLR2 (0.41) | KMT2AL3MBTL1KDM1AMAOBTLR2 | |
| SCHEMBL17101892 | 0.86 | KCNA3 (0.40) | KMT2AL3MBTL1KDM1AMAOBTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163773-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-8163773-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-8163773-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20090233920-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| US-20090233920-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| US-20080194629-A1 | 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors | BAESCHLIN DANIEL KASPAR | 2008-08-14 | — | — | US | disclosed |
| EP-1879882-A1 | 3 -M0N0- AND 3 , 5-DISUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Novartis AG (CH) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007006534-A2 | PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006117183-A1 | 3 -M0N0- AND 3 , 5-DISUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233920-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | KMT2A 3192/4885L3MBTL1 3191/4885BTK 1945/4885 |
| US-20080194629-A1 | 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors | REN, ACE, AGTR1 | KMT2A 2465/4885L3MBTL1 4487/4885BTK 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.